Fisher & Paykel Healthcare Corporation Limited (NZSX:FPH, ASX:FPH) advise that Donal O’Dwyer has been appointed as an additional non-executive director of the company effective 1 December 2012.
“As part of the Board’s ongoing refreshment process and following the indication from Gary Paykel and Nigel Evans that they plan to retire from the Board following the ASM next year, Donal is the first of the two new director appointments we will be making and will help to ensure a smooth transition when Gary and Nigel retire” said Chairman Tony Carter.
The company will next year commence the search for a second new director to join the Board.
“With over 20 years’ experience as a senior executive in the global cardiovascular and medical device industries, Donal is extremely well qualified to contribute to Fisher & Paykel Healthcare’s board at a time when we are continuing to expand our international presence.”
“Donal combines extensive governance experience with a strong entrepreneurial record from his time at Cordis Cardiology and Baxter Healthcare” said Mr Carter.
From 1996 to 2003, Mr O’Dwyer worked for Cordis Cardiology, the cardiology division of Johnson & Johnson’s Cordis Corporation, initially as its president (Europe) and from 2000 to 2003 as its worldwide president. Prior to joining Cordis, Mr O’Dwyer worked for 12 years with Baxter Healthcare, rising from plant manager in Ireland to president of the Cardiovascular Group, Europe, now Edwards Lifesciences.
Mr O’Dwyer is currently Chairman of Atcor Medical Pty Limited as well as being a non-executive director of Cochlear Limited, Sunshine Heart Inc and Mesoblast Limited. Mr O’Dwyer is resident in Australia, is a qualified civil engineer and has an MBA.
The Fisher & Paykel Healthcare board has determined that Mr O’Dwyer will be an independent director.
“Donal will undoubtedly bring great insights and experience to our board, and we look forward to working alongside him to deliver growth in value to our shareholders” Tony Carter said.
About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in respiratory care, acute care and the treatment of obstructive sleep apnea. The company’s products are sold in over 120 countries worldwide. For more information about the company visit www.fphcare.com
Contact: Tony Barclay, Company Secretary on +64 9 574 0119.
Appointment of New Director
Find clinical evidence and practice guidelines for delivering nasal high flow (aka HFNC) therapy.
Providing Optimal Humidity for intubated patients
Featuring under nose NIV masks (F&P Visairo) and full face NIV masks - (F&P Nivairo), with vented and non-vented options to suit your hospital NIV mask needs.
Establish effective spontaneous breathing or assist ventilation of the lungs
Respiratory support that replaces spontaneous breathing
Noninvasive respiratory support that provides a continuous distending pressure
Noninvasive respiratory support that delivers high flows of blended air and oxygen
Designed to work in harmony with the way patients naturally breathe while they sleep
F&P SleepStyle - designed to strike the balance between comfort and effective treatment